Cyrus Chowdhury
Managing Director
Cyrus Chowdhury was a Managing Director of CBPartners.
Connect with Cyrus Chowdhury
Published Articles
November 22, 2017 | Blogs
WHO Stands to Benefit the most from the Biosimilars Prequalification Programme?
November 6, 2017 | Blogs
STRIMVELIS™ – The Proof Is In The Messaging
In an unprecedented move, the UK's National Institute for Health and Care Excellence (NICE) recently recommended NHS funding of GSK's gene therapy STRIMVELIS™ for an ultra-orphan immunodeficiency disorder ADA-SCID1 – also dubbed the “Bubble Baby Syndrome” priced at EUR 594,000. Given NICE’s resistance to such high per-patient therapy costs, CBPartners investigates how GSK was able to defend the value positioning of the STRIMVELIS™ to NICE.
October 16, 2017 | Blogs
Reframing the Opportunity: PDx Hope for Breast Cancer
October is breast cancer awareness month, and In light of our recent PDx (PD1 / PD-L1) analysis, CBPartners decided to take a closer look at the potential for these paradigm-shifting therapies to make a difference for patients diagnosed with breast cancer.
September 17, 2017 | Blogs
Does the Fate of MS Pricing Lie in the Hands of Politicians or Manufacturers?
Yet another drug pricing debate has started to brew in the USA, with its epicentre right in DC. Two Democratic members of the US House (Elijah Cummings (D-MD) and Peter Welch (D-VT)), announced that they are launching an investigation into the pricing of disease-modifying treatments for multiple sclerosis (MS). CBPartners investigates MS pricing in the political context.
August 18, 2017 | Blogs
The New AIFA Algorithm For Assessing ‘Innovativeness’ Of New Products In Italy: So What?
In April 2017, AIFA (Agenzia Italiana del Farmaco, Italian Medicines Agency) released a new algorithm to assess and evaluate the level of innovativeness of new drugs aimed to get reimbursement by the SSN (Sistema Sanitario Nazionale, National Health System) through the EUR 1 billion fund made available by the Italian MoH (Ministero della Salute, Ministry of Health) for innovative therapies. CBPartners investigates the impact that this has.